Leading private capital initiatives with a focus on growth-stage healthcare and tech companies, he combines operational leadership, portfolio company governance, and deal execution experience. Scott M. Freund has served in senior operating and investment roles across healthcare services and healthtech, contributing to M&A, strategic partnerships and board oversight. He is known for aligning management incentives with growth capital deployment and improving commercial metrics to prepare exits to strategic buyers and public markets. Markets view him as a pragmatic operator-investor capable of bridging clinical strategy and commercial scale.
Leading private capital initiatives with a focus on growth-stage healthcare and tech companies, he combines operational leadership, portfolio company governance, and deal execution experience. Scott M. Freund has served in senior operating and investment roles across healthcare services and healthtech, contributing to M&A, strategic partnerships and board oversight. He is known for aligning management incentives with growth capital deployment and improving commercial metrics to prepare exits to strategic buyers and public markets. Markets view him as a pragmatic operator-investor capable of bridging clinical strategy and commercial scale.
Focuses on growth-stage healthcare and healthtech opportunities where operational improvement and clinical-commercial alignment can drive valuation uplift. Prefers sector-aware, control-oriented growth capital and minority-plus investments that pair capital with board-level governance and incentive alignment. Emphasizes measurable commercial KPIs, disciplined exit orientation toward strategics and IPOs, and pragmatic risk mitigation via active portfolio operating involvement and staged capital deployment.
Focuses on growth-stage healthcare and healthtech opportunities where operational improvement and clinical-commercial alignment can drive valuation uplift. Prefers sector-aware, control-oriented growth capital and minority-plus investments that pair capital with board-level governance and incentive alignment. Emphasizes measurable commercial KPIs, disciplined exit orientation toward strategics and IPOs, and pragmatic risk mitigation via active portfolio operating involvement and staged capital deployment.
| Trades 386 | Longs Won 284/386 73% | Profit Factor 15.17 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $928,691.46 |
| Average Win $208,922.14 | Best Trade (Jul 10) $15.5M | Sharpe Ratio -921.89 |
| Average Loss -$38,344.21 | Worst Trade (Mar 30) -$600,912.81 | Z-Score 8.58 (100%) |
| Commissions $0 | Avg. Trade Length 10m 1d | Expectancy $143,582.33 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.01% |
| Consecutive Losing Trades | 6,757 | 6,081 | 5,405 | 4,730 | 4,054 | 3,378 | 2,703 | 2,027 | 1,351 | 676 |